These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20600734)

  • 1. Evaluation of carboxymethyl-beta-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine.
    Mady FM; Abou-Taleb AE; Khaled KA; Yamasaki K; Iohara D; Taguchi K; Anraku M; Hirayama F; Uekama K; Otagiri M
    Int J Pharm; 2010 Sep; 397(1-2):1-8. PubMed ID: 20600734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of the aqueous solubility and masking the bitter taste of famotidine using drug/SBE-beta-CyD/povidone K30 complexation approach.
    Mady FM; Abou-Taleb AE; Khaled KA; Yamasaki K; Iohara D; Ishiguro T; Hirayama F; Uekama K; Otagiri M
    J Pharm Sci; 2010 Oct; 99(10):4285-94. PubMed ID: 20737636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced oral absorption of saquinavir with Methyl-Beta-Cyclodextrin-Preparation and in vitro and in vivo evaluation.
    Pathak SM; Musmade P; Dengle S; Karthik A; Bhat K; Udupa N
    Eur J Pharm Sci; 2010 Nov; 41(3-4):440-51. PubMed ID: 20656025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of P-glycoprotein to the enhancing effects of dimethyl-beta-cyclodextrin on oral bioavailability of tacrolimus.
    Arima H; Yunomae K; Hirayama F; Uekama K
    J Pharmacol Exp Ther; 2001 May; 297(2):547-55. PubMed ID: 11303042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slow-release of famotidine from tablets consisting of chitosan/sulfobutyl ether β-cyclodextrin composites.
    Anraku M; Hiraga A; Iohara D; Pipkin JD; Uekama K; Hirayama F
    Int J Pharm; 2015 Jun; 487(1-2):142-7. PubMed ID: 25882010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taste masking microspheres for orally disintegrating tablets.
    Xu J; Bovet LL; Zhao K
    Int J Pharm; 2008 Jul; 359(1-2):63-9. PubMed ID: 18455893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental, molecular docking investigations and bioavailability study on the inclusion complexes of finasteride and cyclodextrins.
    Mady FM; Farghaly Aly U
    Drug Des Devel Ther; 2017; 11():1681-1692. PubMed ID: 28652706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and biological evaluation of glimepiride-cyclodextrin-polymer systems.
    Ammar HO; Salama HA; Ghorab M; Mahmoud AA
    Int J Pharm; 2006 Feb; 309(1-2):129-38. PubMed ID: 16377107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of solubility and oral bioavailability of rutin by complexation with 2-hydroxypropyl-beta-cyclodextrin.
    Miyake K; Arima H; Hirayama F; Yamamoto M; Horikawa T; Sumiyoshi H; Noda S; Uekama K
    Pharm Dev Technol; 2000; 5(3):399-407. PubMed ID: 10934740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evaluation of oral tablet formulations prepared with ketoconazole and hydroxypropyl-beta-cyclodextrin.
    Taneri F; Ozcan I; Guneri T
    Drug Deliv; 2010 Apr; 17(3):152-7. PubMed ID: 20148713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.
    Arima H; Yunomae K; Miyake K; Irie T; Hirayama F; Uekama K
    J Pharm Sci; 2001 Jun; 90(6):690-701. PubMed ID: 11357172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of oral bioavailability of fenbufen by cyclodextrin complexations.
    Miyaji T; Inoue Y; Acartürk F; Imai T; Otagiri M; Uekama K
    Acta Pharm Nord; 1992; 4(1):17-22. PubMed ID: 1515048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation.
    Fahmy RH; Kassem MA
    Eur J Pharm Biopharm; 2008 Aug; 69(3):993-1003. PubMed ID: 18396390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of sulfobutyl ether-β-cyclodextrin on bioavailability of insulin glargine and blood glucose level after subcutaneous injection to rats.
    Uehata K; Anno T; Hayashida K; Motoyama K; Hirayama F; Ono N; Pipkin JD; Uekama K; Arima H
    Int J Pharm; 2011 Oct; 419(1-2):71-6. PubMed ID: 21803140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation and evaluation of meloxicam oral disintegrating tablet with dissolution enhanced by combination of cyclodextrin and ion exchange resins.
    Samprasit W; Akkaramongkolporn P; Ngawhirunpat T; Rojanarata T; Opanasopit P
    Drug Dev Ind Pharm; 2015 Jun; 41(6):1006-16. PubMed ID: 24865111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-beta-cyclodextrin, not 2,6-di-O-methyl-alpha-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells.
    Motoyama K; Kameyama K; Onodera R; Araki N; Hirayama F; Uekama K; Arima H
    Eur J Pharm Sci; 2009 Oct; 38(3):249-61. PubMed ID: 19664706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation and evaluation of taste masked famotidine formulation using drug/beta-cyclodextrin/polymer ternary complexation approach.
    Patel AR; Vavia PR
    AAPS PharmSciTech; 2008; 9(2):544-50. PubMed ID: 18431648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication of inclusion complexation of glimepiride in cyclodextrin-polymer systems on its dissolution, stability and therapeutic efficacy.
    Ammar HO; Salama HA; Ghorab M; Mahmoud AA
    Int J Pharm; 2006 Aug; 320(1-2):53-7. PubMed ID: 16701974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin.
    Ventura CA; Tommasini S; Falcone A; Giannone I; Paolino D; Sdrafkakis V; Mondello MR; Puglisi G
    Int J Pharm; 2006 May; 314(1):37-45. PubMed ID: 16581211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of parenteral formulation for a novel angiogenesis inhibitor, CKD-732 through complexation with hydroxypropyl-beta-cyclodextrin.
    Kim JH; Lee SK; Ki MH; Choi WK; Ahn SK; Shin HJ; Hong CI
    Int J Pharm; 2004 Mar; 272(1-2):79-89. PubMed ID: 15019071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.